Santiago P. A.
- Country
- France
- Department
- #4302: Oncology
Research Overview
- Phase 1 Evaluation of BL-B01D1 Safety, Tolerability, and Efficacy in Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors
- Evaluation of STX-721 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Specific Mutations
- Evaluation of Safety and Anti-tumor Activity of TT125-802 with Adagrasib or Osimertinib in Advanced Non-Small Cell Lung Cancer Patients
Data & Insights
Has run more than one trial at 60 of 155 partner sites.
Specializations
Thoracic Oncology
The investigator specializes in treating complex thoracic malignancies, with particular emphasis on small cell lung cancer and neuroendocrine carcinomas. Their research encompasses innovative therapeutic approaches for these challenging conditions.
- Advanced Small Cell Lung Cancer
- Neuroendocrine Tumor Management
- Novel Therapeutic Applications
Their work includes evaluation of novel compounds and their effects on these specific tumor types.
Thymic Malignancies
The investigator focuses on treating rare thoracic cancers, specifically type B3 thymoma and thymic carcinoma. Their expertise extends to managing patients who have undergone prior chemotherapy treatments.
- Advanced Thymic Carcinoma
- Type B3 Thymoma Treatment
- Immunotherapy Applications
Their research explores immunotherapeutic approaches for patients with thymic malignancies.
Therapeutic Innovation
The investigator's work encompasses evaluation of immunotherapy strategies and targeted therapies for thoracic cancers. Their research includes assessment of treatment outcomes in previously treated patients.
- Treatment Response Assessment
- Advanced Disease Management
- Therapeutic Sequencing
Their focus includes developing treatment strategies for patients with progressive disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.